- Wills, Anne‐Marie A;
- Eberly, Shirley;
- Tennis, Marsha;
- Lang, Anthony E;
- Messing, Susan;
- Togasaki, Daniel;
- Tanner, Caroline M;
- Kamp, Cornelia;
- Chen, Jiang‐Fan;
- Oakes, David;
- McDermott, Michael P;
- Schwarzschild, Michael A;
- Group, on behalf of the Parkinson Study
Background
Adenosine A2A receptor antagonists reduce or prevent the development of dyskinesia in animal models of levodopa-induced dyskinesia.Methods
We examined the association between self-reported intake of the A2A receptor antagonist caffeine and time to dyskinesia in the Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) and CALM Cohort extension studies, using a Cox proportional hazards model adjusting for age, baseline Parkinson's severity, site, and initial treatment with pramipexole or levodopa.Results
For subjects who consumed >12 ounces of coffee/day, the adjusted hazard ratio for the development of dyskinesia was 0.61 (95% CI, 0.37-1.01) compared with subjects who consumed <4 ounces/day. For subjects who consumed between 4 and 12 ounces/day, the adjusted hazard ratio was 0.73 (95% CI, 0.46-1.15; test for trend, P = .05).Conclusions
These results support the possibility that caffeine may reduce the likelihood of developing dyskinesia.